Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)

This study has been completed.
Targacept Inc.
Information provided by:
AstraZeneca Identifier:
First received: May 21, 2008
Last updated: October 29, 2009
Last verified: October 2009
A 3-way cross-over trial of two weeks of treatment with three drug conditions. AZD3480 will be given in doses of (A) 5mg/day, (B) 50 mg/day and (C) placebo to 24 non-smoking adults with DSM-IV confirmed ADHD. Three week washout between each treatment period. CYP2D6 genotyping will be completed at screening and slow metabolisers will be excluded from participation in this study. Cognitive, ADHD symptom, safety and pharmacokinetic (PK) assessments will be made during each treatment period. Safety and tolerability assessments will be a major component of the trial and all serious adverse events (SAE) will be immediately (within 24 hours) reported to both Targacept and to AstraZenca.

Condition Intervention Phase
Drug: Placebo
Drug: AZD3480
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The Total Symptoms Scale Score (of ADHD) of the Connors Adult ADHD Rating Scale-Investigator Rating (CAARS-INV). [ Time Frame: Visit 1, 2, 3, 4, 5, 8, 9, 10,13, 14 and 15 ]

Secondary Outcome Measures:
  • Clinical Global Impressions Scales (NIMH 1985) [ Time Frame: Visit 1, 2, 3, 4, 5, 8, 9, 10, 13, 14,15 ]
  • CDR computerized cognitive battery [ Time Frame: 2, 3, 5, 8, 10, 13, 15 ]
  • CNRU computerized cognitive battery [ Time Frame: 2, 3, 5, 8, 10, 13, 15 ]

Estimated Enrollment: 24
Study Start Date: May 2008
Study Completion Date: July 2009
Arms Assigned Interventions
Placebo Comparator: 1 Drug: Placebo
Experimental: 2 Drug: AZD3480
Capsules 5 mg/day (once a day) for 2 weeks
Experimental: 3 Drug: AZD3480
Capsules 50 mg/day (once a day) for 2 weeks


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of DSM-IV ADHD
  • Score of equal or more than 2 on at least six of nine items in at least one of the subscales of the Connor´s Adult ADHD Rating Scale (CAARS-INV)
  • Score of equal or more than 4 (at least moderate severity) on the Clinical Global Impressions-Severity (CGI-S) test

Exclusion Criteria:

  • Current DSM-IV Axis I psychiatric disorder (other than ADHD)
  • Current user of cigarettes or other nicotine-containing product.
  • Slow metabolizers as indicated by CYP2D6 genotyping.
  • Use of drugs affecting cognitive function within 8 weeks prior to enrollment visit or intended use during the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00683462

United States, Vermont
Research Site
Burlington, Vermont, United States
Sponsors and Collaborators
Targacept Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Hans-Göran Hårdemark, MD, PhD, Medical Science Director AZD3480, AstraZeneca R&D, Södertälje Identifier: NCT00683462     History of Changes
Obsolete Identifiers: NCT00683215
Other Study ID Numbers: TC-1734-226-CRD-005
Study First Received: May 21, 2008
Last Updated: October 29, 2009

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders processed this record on May 25, 2017